Drugs / Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells
last change Apr 2021 re-read 2 minutes ago

Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells

Cell therapy

Developed for
acute myeloid leukemia · B-cell chronic lymphocytic leukemia · Hodgkins lymphoma
Investigated by
National Cancer Institute (NCI) · Robert Lowsky

Trials 1 · a red edge is where a trial was stopped

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02424968 Jun 2015 → Jul 2020 B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia +1 Robert Lowsky Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT02424968
Modality Cell therapy “Giving an infusion of the donor's white blood cells, such as CD8+ memory T-cells” NCT02424968
Route Intravenous “Receive CD8+ memory T-cells via IV” NCT02424968